Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2022 Sep;76(3):558-560.
doi: 10.1002/hep.32361. Epub 2022 Mar 3.

Will inhibition of cellular crosstalk resolve liver fibrosis?

Edward N Harris  1
Affiliations
Editorial

Will inhibition of cellular crosstalk resolve liver fibrosis?

Edward N Harris. Hepatology. 2022 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

Dr. Harris consults for NGM Biopharmaceuticals.

Figures

FIGURE 1
FIGURE 1
CCl4 administration to mice induces oxidative stress in hepatocytes, which allow for the secretion of VEGF and LECT2 for binding with VEGFR and Tie1, respectively, in the endothelium. This results in increased capillarization and increased central vessel bridging and decreased numbers of periportal vessel markers leading to fibrogenesis. Blocking VEGFR with the monoclonal antibody, bevacizumab, and down-regulation of LECT2 by siRNA inhibition prevents fibrosis. siRNA, short interfering RNA
See this image and copyright information in PMC

Comment on

References

    1. Heyens LJM, Busschts D, Koek GH, Robaeys G, Francque S. Liver fibrosis in non-alcoholic fatty liver disease: from liver biopsy to non-invasive biomarkers in diagnosis and treatment. Front Med (Lausanne). 2021;8:615978. - PMC - PubMed
    1. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:245–66. - PMC - PubMed
    1. Cheemerla S, Balakrishnan M. Global epidemiology of chronic liver disease. Clin Liver Dis (Hoboken). 2021;17:365–70. - PMC - PubMed
    1. Lin Y, Dong MQ, Liu ZM, Xu M, Huang ZH, Liu HJ. A strategy of vascular-targeted therapy for liver fibrosis. Hepatology. 2021. Dec 23. 10.1002/hep.32299. [Epub ahead of print] - DOI - PMC - PubMed
    1. Coulon S, Heindryckx F, Geerts A, Van Steenkiste C, Colle I, Van Vlierberghe H. Angiogenesis in chronic liver disease and its complications. Liver Int. 2011;31:146–62. - PubMed